Robert E. Coleman

58.8k total citations · 10 hit papers
563 papers, 34.3k citations indexed

About

Robert E. Coleman is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Robert E. Coleman has authored 563 papers receiving a total of 34.3k indexed citations (citations by other indexed papers that have themselves been cited), including 347 papers in Oncology, 243 papers in Radiology, Nuclear Medicine and Imaging and 157 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Robert E. Coleman's work include Bone health and treatments (255 papers), Radiopharmaceutical Chemistry and Applications (177 papers) and Cancer Diagnosis and Treatment (63 papers). Robert E. Coleman is often cited by papers focused on Bone health and treatments (255 papers), Radiopharmaceutical Chemistry and Applications (177 papers) and Cancer Diagnosis and Treatment (63 papers). Robert E. Coleman collaborates with scholars based in United Kingdom, United States and Canada. Robert E. Coleman's co-authors include Allan Lipton, Janet E. Brown, Ingunn Holen, Richard J. Cook, Peyman Hadji, Helen Neville-Webbe, Anthony Howell, Pierre Major, Fred Saad and John J. Seaman and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and JAMA.

In The Last Decade

Robert E. Coleman

552 papers receiving 33.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity

2006 1.8k citations Robert E. Coleman Clinical Cancer Research profile →
Metastatic bone disease: clinical features, pathophysiology and treatment strategies

2001 1.4k citations Robert E. Coleman Cancer Treatment Reviews profile →
Skeletal complications of malignancy

1997 1.2k citations Robert E. Coleman profile →
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.

2002 676 citations Anthony Howell, John R. Mackey et al. PubMed profile →
Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma

2003 657 citations Anthony Howell, John R. Mackey et al. profile →
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

2012 572 citations Robert E. Coleman et al. profile →
Pathologic fractures correlate with reduced survival in patients with malignant bone disease

2007 492 citations Robert E. Coleman et al. profile →
Bone health in cancer patients: ESMO Clinical Practice Guidelines

2014 401 citations Robert E. Coleman, Jean‐Jacques Body et al. Annals of Oncology profile →
Bone metastases

2020 347 citations Robert E. Coleman, Edward Chow et al. profile →
Bone health in cancer: ESMO Clinical Practice Guidelines

2020 294 citations Robert E. Coleman, Peyman Hadji et al. Annals of Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Robert E. Coleman	21.7k	10.6k	8.6k	6.3k	5.2k	563	34.3k
Allan Lipton	15.7k 0.7×	5.8k 0.5×	5.0k 0.6×	3.1k 0.5×	4.8k 0.9×	411	21.3k
Fred Saad	15.4k 0.7×	8.7k 0.8×	23.9k 2.8×	5.3k 0.8×	7.6k 1.5×	1.2k	36.7k
Abass Alavi	4.1k 0.2×	14.2k 1.3×	8.0k 0.9×	7.8k 1.2×	3.4k 0.7×	1.1k	37.2k
Michael A. Carducci	11.4k 0.5×	4.9k 0.5×	17.4k 2.0×	2.2k 0.3×	10.8k 2.1×	591	32.3k
Paul Emery	5.0k 0.2×	6.8k 0.6×	2.7k 0.3×	5.4k 0.9×	5.8k 1.1×	1.0k	67.0k
John R. Mackey	14.8k 0.7×	1.9k 0.2×	4.6k 0.5×	2.0k 0.3×	5.9k 1.1×	335	24.6k
Julie R. Gralow	12.5k 0.6×	4.6k 0.4×	4.2k 0.5×	1.0k 0.2×	4.0k 0.8×	283	20.4k
Leslie L. Robison	10.8k 0.5×	2.8k 0.3×	8.4k 1.0×	3.8k 0.6×	6.5k 1.3×	936	58.3k
T. Huizinga	4.4k 0.2×	8.5k 0.8×	2.0k 0.2×	3.0k 0.5×	6.6k 1.3×	1.1k	49.4k
Hang Lee	4.2k 0.2×	3.2k 0.3×	3.1k 0.4×	5.5k 0.9×	4.7k 0.9×	440	26.2k

Countries citing papers authored by Robert E. Coleman

Since Specialization

Citations

This map shows the geographic impact of Robert E. Coleman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert E. Coleman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert E. Coleman more than expected).

Fields of papers citing papers by Robert E. Coleman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert E. Coleman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert E. Coleman. The network helps show where Robert E. Coleman may publish in the future.

Co-authorship network of co-authors of Robert E. Coleman

This figure shows the co-authorship network connecting the top 25 collaborators of Robert E. Coleman. A scholar is included among the top collaborators of Robert E. Coleman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert E. Coleman. Robert E. Coleman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kittaneh, Muaiad, Sunil Badve, Humberto Caldera, et al.. (2020). Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). Clinical Breast Cancer. 20(3). 183–193. 12 indexed citations

Coleman, Robert E., Peyman Hadji, Jean‐Jacques Body, et al.. (2020). Bone health in cancer: ESMO Clinical Practice Guidelines. Annals of Oncology. 31(12). 1650–1663. 294 indexed citations breakdown →

Coleman, Robert E.. (2020). Bisphosphonates and breast cancer – From cautious palliation to saving lives. Bone. 140. 115570–115570. 18 indexed citations

Tulotta, Claudia, Diane V. Lefley, Walter M. Gregory, et al.. (2019). Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment. Clinical Cancer Research. 25(9). 2769–2782. 136 indexed citations

Mahtani, Reshma, Sunil Badve, Humberto Caldera, et al.. (2019). A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. Clinical Breast Cancer. 20(3). e251–e260. 17 indexed citations

Ubellacker, Jessalyn M., Ninib Baryawno, Nicolas Sévère, et al.. (2018). Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer. Cancer Research. 78(18). 5300–5314. 23 indexed citations

Abraham, Jame, Humberto Caldera, Robert E. Coleman, et al.. (2018). Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). Breast Cancer Research and Treatment. 169(1). 1–7. 9 indexed citations

Abraham, Jame, Robert E. Coleman, Anthony Elias, et al.. (2018). Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG). Breast Cancer Research and Treatment. 171(1). 11–20. 29 indexed citations

Anderson, Richard A., et al.. (2017). The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. European Journal of Cancer. 87. 58–64. 57 indexed citations

10.

Baselga, José, Robert E. Coleman, Javier Cortés, & Wolfgang Janni. (2017). Advances in the management of HER2-positive early breast cancer. Critical Reviews in Oncology/Hematology. 119. 113–122. 41 indexed citations

11.

D’Oronzo, Stella, Janet E. Brown, & Robert E. Coleman. (2017). The value of biomarkers in bone metastasis. European Journal of Cancer Care. 26(6). e12725–e12725. 37 indexed citations

12.

Singh, Kamaljit, Sarah Gillett, Jan Everard, et al.. (2014). Evolution of a specialist gestational trophoblastic disease service with a major nursing component: the Sheffield, United Kingdom, experience.. PubMed. 59(5-6). 195–8. 7 indexed citations

13.

Agarwal, Roshan, Philip Savage, Dee Short, et al.. (2014). Management and survival of patients with FIGO high-risk gestational trophoblastic neoplasia: the U.K. experience, 1995-2010.. PubMed. 59(1-2). 7–12. 21 indexed citations

14.

Coleman, Robert E., Jean‐Jacques Body, Matti Aapro, Peyman Hadji, & Jørn Herrstedt. (2014). Bone health in cancer patients: ESMO Clinical Practice Guidelines. Annals of Oncology. 25. iii124–iii137. 401 indexed citations breakdown →

15.

Winter, Matthew & Robert E. Coleman. (2012). Bisphosphonates in the Adjuvant Treatment of Breast Cancer. Clinical Oncology. 25(2). 135–145. 21 indexed citations

16.

Coleman, Robert E. & Sharon H. Giordano. (2011). Adjuvant treatment with zoledronic acid in stage II/III breast cancer: The AZURE trial. 36(3). 1 indexed citations

17.

Amir, Eitan, Mark Clemons, Colin A. Purdie, et al.. (2011). Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treatment Reviews. 38(6). 708–714. 139 indexed citations

18.

Hatton, M., et al.. (2010). Review of Testing and Use of Adjuvant Trastuzumab across a Cancer Network — Are We Treating the Right Patients?. Clinical Oncology. 22(4). 289–293. 13 indexed citations

19.

Eastell, Richard, Judith E. Adams, Robert E. Coleman, et al.. (2008). Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230. Journal of Clinical Oncology. 26(7). 1051–1057. 306 indexed citations

20.

Lester, J. & Robert E. Coleman. (2005). The use of bisphosphonates in breast cancer. The Journal of the British Menopause Society. 11(1). 12–17. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact